FindTrial
Sign In

Effect of timing of belimumab administration on the treatment of Childhood-onset Systemic Lupus Erythematosus: a prospective analysis of results from the multicenter observational study in China

Effect of timing of belimumab administration on the treatment of Childhood-onset Systemic Lupus Erythematosus: a prospective analysis of results from the multicenter observational study in China

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100042713
Enrollment
Unknown
Registered
2021-01-26
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood-onset Systemic Lupus Erythematosus

Interventions

group by the course of disease:Nil

Sponsors

Children's Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 5 to 17 years; 2. Diagnostic criteria: according to the American rheumatic Association (ACR) classification of SLE in 1997 or European rheumatic Association / American rheumatic Association classification of systemic lupus erythematosus (EULAR / ACR) in 2019; 3. Children who are evaluated by doctors as being able to be treated with belimumab.

Exclusion criteria

Exclusion criteria: Any patients participating in other clinical trials related to SLE.

Design outcomes

Primary

MeasureTime frame
SELENA-SLEDAI score;SDI;SFI;PGA;Prednisone daily dose (mg / kg);height;weight;—

Countries

China

Contacts

Public ContactTang Xuemei

Children's Hospital Affiliated to Chongqing Medical University

tangxuemei2008@163.com+86 13012352441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026